Esperion Therapeutics Inc (ESPR) Return on Assets ROA from the first quarter of 2026 to first quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Esperion Therapeutics Inc   (NASDAQ: ESPR)


Esperion Therapeutics Inc 's ROA from the first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Esperion Therapeutics Inc 's ROA in the first quarter of 2026?
Esperion Therapeutics Inc recorded a cumulative net loss of $-7 million during 12 months ending in the first quarter of 2026, resulting in a negative return on assets (ROA) of -1.83%.

However, within the Healthcare sector 230 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2026 quarter, so far to 2743, from total ROA ranking in the fourth quarter of 2025 at 3536.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Total Assets Change 44.12 % 42.69 % 17.15 % -0.76 % -12.81 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -7 -23 -106 -104 -153
Return On Assets (TTM) -1.83 % -6.11 % -31.43 % -32.15 % -47.26 %
ESPR's Total Ranking # 2743 # 3536 # 3780 # 3816 # 4092
Total Assets (TTM) in million 460 463 361 343 319
Seq. Total Assets Change -0.68 % 28.35 % 5.2 % 7.46 % -1.66 %
Seq. Net Income Change - - - - -

ESPR's 5 Years Annual ROA >> Back to ESPR Management Effectiveness >> Compare ESPR ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 77
Sector # 231
Overall # 2723

Return On Assets Statistics
High Average Low
-1.81 %
-51.75 %
-111.59 %
(Mar 31 2026)   (Jun 30 2021)



  News about Esperion Therapeutics Inc Return on Assets ROA

Esperion Therapeutics Balancing Promise and Performance Amidst Market Turbulence,

Navigating the Ups and Downs: The Rollercoaster Journey of Esperion TherapeuticsEsperion Therapeutics Inc. (NASDAQ: ESPR) is a biotechnology company focused on developing and commercializing innovative therapies for patients with cardiovascular diseases. Recently, shares of Esperion have experienced significant fluctuations, sparking interest and concern among investors. As the landscape evolves, let’s interpret recent developments surrounding this intriguing company.On December 15, 2024, Needham and Company reaffirmed their Buy rating for Esperion Therapeutics, following a research report that signaled optimism about the company s prospects. This endorsement from a reputable financial entity suggests that analysts believe in the potential for significant long-term growth, despite recent stock performance challenges.



Financial Statements
Esperion Therapeutics Inc 's Assets $ 460 million ESPR's Balance sheet
Esperion Therapeutics Inc 's Income $ -25 million Quarterly ESPR's Income Statement
ESPR's Income by Division See ESPR's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 36.85 % 68.21 % -18.54 % -35.3 % 8.02 %
Total Assets in million 463 338 201 247 382
Y / Y Net Income Change - - - - -
Net Income in million -23 -52 -209 -234 -269
Annual Return On Assets -4.9 % -15.3 % -104.04 % -94.64 % -70.52 %

ESPR's 5 Years Annual ROA >> Back to ESPR Management Effectiveness >> Compare ESPR ROA to its Competitors



More Return On Assets Ratios
ESPR's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ESPR's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ESPR's Competitors
Subscribers only: Roa for Esperion Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for ESPR's Customers

You may also want to know
ESPR's Roi ESPR's Inventory Turnover Ratio ESPR's Growth Rates ESPR's Dividend Comparisons
ESPR's Profitability Ratios ESPR's Asset Turnover Ratio ESPR's Dividend Growth
ESPR's Roe ESPR's Valuation Ratios ESPR's Financial Strength Ratios ESPR's Dividend Payout Ratio



Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector ROA

Date modified: 2026-09-18T13:11:06+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.